title: Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response.
abstract: OBJECTIVE
  The primary aim of this trial was to assess the rate of pathologic complete responses (pCR) of doxorubicin/cyclophosphamide (AC) followed by bevacizumab/docetaxel (BT), as neoadjuvant therapy for breast cancer (BC). Furthermore, the association between biomarkers and the pCR was explored.
  
  
  METHODS
  Patients with HER-negative operable stage II-III BC ≥ 2 cm were enrolled. Four cycles of AC (A 60 mg/m(2) and C 600 mg/m(2), every 3 weeks) followed by 4 cycles of BT (B 15 mg/kg and T 75 mg/m(2), every 3 weeks), were planned. A core-biopsy was performed for biological markers assessment.
  
  
  RESULTS
  Seventy-two women were included. Forty-three (63 %) patients were hormone receptor-positive. Sixty-four (89 %) completed the planned treatment, and 66 evaluable patients underwent surgery (92 %): a pCR was achieved in 16 of them (24, 95 % CI 15-36 %). pCR was significantly higher in tumors hormone receptor-negative, and in those with Angiotensin II type 1 receptor (AGTR1) protein overexpression. The overall clinical response rate was 86 % (95 % CI 76-93 %), including 42 complete responses. No unexpected toxicities or treatment-related deaths were observed.
  
  
  CONCLUSIONS
  This regimen showed a remarkable clinical and pathological activity: the suggested relation between pCR and AGTR1 overexpression should be confirmed in larger trials.
authors: Servicio de Oncología Médica, Complejo Hospitalario de Jaén, Avda. del Ejército Español, 10, 23007, Jaén, Spain, oncopsr@yahoo.es.
authors: P
authors: P
authors: Sánchez-Rovira
authors: M A
authors: MA
authors: Seguí
authors: A
authors: A
authors: Llombart
authors: E
authors: E
authors: Aranda
authors: A
authors: A
authors: Antón
authors: A
authors: A
authors: Sánchez
authors: M
authors: M
authors: Lomas
authors: A
authors: A
authors: Jaén
authors: M
authors: M
authors: Fernández
authors: I
authors: I
authors: Porras
authors: E
authors: E
authors: Dalmau
authors: S
authors: S
authors: Morales
authors: J
authors: J
authors: de la Haba-Rodríguez
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D014408:Biomarkers, Tumor / Q000378:metabolism; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D018275:Carcinoma, Lobular / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D003520:Cyclophosphamide / Q000008:administration & dosage; D000077143:Docetaxel; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D011300:Preoperative Care; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D012074:Remission Induction; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D014408:Biomarkers, Tumor; D003520:Cyclophosphamide; D000077143:Docetaxel; D004317:Doxorubicin; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D043823:Taxoids
references: J Clin Oncol. 2006 Feb 10;24(5):769-77
references: 16391297
references: Clin Breast Cancer. 2007 Apr;7(7):559-64
references: 17509165
references: J Natl Cancer Inst. 2005 Aug 17;97(16):1180-4
references: 16106022
references: Control Clin Trials. 1989 Mar;10(1):1-10
references: 2702835
references: J Clin Oncol. 2006 Mar 1;24(7):1037-44
references: 16505422
references: Clin Cancer Res. 2008 Sep 15;14(18):5893-9
references: 18794102
references: J Clin Oncol. 1998 Jan;16(1):107-14
references: 9440730
references: Eur J Surg Oncol. 2009 Oct;35(10):1048-54
references: 19250795
references: Clin Breast Cancer. 2002 Oct;3 Suppl 2:S69-74
references: 12435290
references: Ann Surg Oncol. 2009 Jun;16(6):1619-28
references: 19333654
references: Anticancer Drugs. 2009 Mar;20(3):197-203
references: 19182679
references: J Clin Oncol. 2006 May 1;24(13):2019-27
references: 16606972
references: Clin Breast Cancer. 2010 Aug 1;10(4):275-80
references: 20705559
references: Br J Cancer. 2008 Nov 18;99(10):1564-71
references: 18941458
references: Clin Cancer Res. 2009 May 15;15(10):3583-90
references: 19417018
references: Am J Clin Oncol. 2010 Oct;33(5):432-7
references: 19952716
references: Nature. 2005 Dec 15;438(7070):967-74
references: 16355214
references: J Clin Oncol. 2008 May 20;26(15):2596; author reply 2596-7
references: 18487578
references: BMC Cancer. 2007 Nov 01;7:203
references: 17976237
references: J Clin Oncol. 1998 Aug;16(8):2672-85
references: 9704717
references: Ann Oncol. 2008 Mar;19(3):465-72
references: 17986623
references: Anticancer Drugs. 2001 Feb;12 Suppl 1:S25-9
references: 11340901
references: N Engl J Med. 2012 Jan 26;366(4):299-309
references: 22276820
references: J Clin Oncol. 2005 Apr 20;23(12):2676-85
references: 15837982
references: Cancer Res. 2001 Apr 15;61(8):3369-72
references: 11309294
references: Clin Cancer Res. 2005 Aug 15;11(16):5678-85
references: 16115903
references: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references: 10655437
references: J Clin Oncol. 2005 May 1;23(13):2988-95
references: 15860854
references: N Engl J Med. 2012 Jan 26;366(4):310-20
references: 22276821
references: J Clin Oncol. 2008 Mar 10;26(8):1275-81
references: 18250347